Sidoti Brokers Reduce Earnings Estimates for Kamada

Key Points

• Sidoti lowered Kamada’s earnings forecasts, cutting its Q3 2026 EPS estimate to $0.10 from $0.12 and reducing estimates across several quarters through 2028, including FY2028 EPS from $0.60 to $0.50.
• Kamada’s latest quarterly results exceeded expectations, with EPS of $0.16 versus the $0.11 consensus and revenue of $54.92 million compared with estimates of $50.84 million.
• Despite the estimate reductions, analyst sentiment remains positive: Kamada has an overall “Buy” rating and a consensus price target of $13.50, versus a recent share price of $8.72.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities research analysts at Sidoti cut their Q3 2026 earnings per share (EPS) estimates for Kamada in a research note issued on Friday, September 25th. Sidoti analyst J. Sidoti now expects that the biotechnology company will earn $0.10 per share for the quarter, down from their previous estimate of $0.12. The consensus estimate for Kamada's current full-year earnings is $0.49 per share. Sidoti also issued estimates for Kamada's Q4 2026 earnings at $0.09 EPS, Q1 2027 earnings at $0.10 EPS, Q2 2027 earnings at $0.11 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.12 EPS, Q1 2028 earnings at $0.11 EPS, Q2 2028 earnings at $0.12 EPS and FY2028 earnings at $0.50 EPS.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. The firm had revenue of $54.92 million for the quarter, compared to analysts' expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Other analysts have also issued reports about the company. Weiss Ratings reiterated a "buy (b-)" rating on shares of Kamada in a research note on Tuesday, September 22nd. Wall Street Zen upgraded Kamada from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 15th. Benchmark reaffirmed a "buy" rating on shares of Kamada in a report on Tuesday, July 21st. UBS Group reiterated a "buy" rating and set a $15.00 price target on shares of Kamada in a research report on Friday, September 18th. Finally, William Blair set a $15.00 price target on shares of Kamada in a report on Tuesday, July 21st. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $13.50.

Kamada Price Performance

NASDAQ:KMDA opened at $8.72 on Monday. The company has a market cap of $501.44 million, a P/E ratio of 22.95, a P/E/G ratio of 0.71 and a beta of 0.88. The stock's fifty day moving average price is $7.87 and its two-hundred day moving average price is $7.89. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35.

Hedge Funds Weigh In On Kamada

A hedge fund recently raised its stake in Kamada stock. Aristides Capital LLC boosted its position in Kamada Ltd. (NASDAQ:KMDA - Free Report) by 4.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,491 shares of the biotechnology company's stock after buying an additional 1,476 shares during the quarter. Aristides Capital LLC owned approximately 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Cuts Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th were given a dividend of $0.17 per share. This is a drop from Kamada's previous annual dividend of $0.25. The ex-dividend date was Thursday, August 27th. This represents a dividend yield of 206.0%. Kamada's dividend payout ratio is currently 31.58%.

Key Kamada News

Here are the key news stories impacting Kamada this week:

• Negative Sentiment: Sidoti cut its Q3 2026 EPS estimate to $0.10 from $0.12 and its Q4 2026 forecast to $0.09 from $0.11. The analyst also reduced estimates for Q1 2027 to $0.10 from $0.11 and Q2 2027 to $0.11 from $0.13. Sidoti earnings estimate revisions for Kamada
• Negative Sentiment: Further reductions affected Q3 2027, now forecast at $0.13 versus $0.14, Q4 2027 at $0.12 versus $0.14, Q1 2028 at $0.11 versus $0.13, and Q2 2028 at $0.12 versus $0.15. Kamada forward earnings estimate revisions
• Negative Sentiment: Sidoti lowered its FY2028 EPS forecast substantially to $0.50 from $0.60, implying weaker expected annual profitability. Although the current-year consensus remains $0.49 per share and the revised FY2028 estimate still reflects growth, the magnitude and breadth of the cuts may weigh on investor sentiment. Kamada FY2028 earnings estimate revision

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company's portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada's principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.